TYO:219A

2 stories mentioning TYO:219AUpdated 22d ago

Every FINWIRES story that references TYO:219A, newest first.

Heartseed Reports First Patient Dosed in Cardiac Remuscularization Therapy Trial

Heartseed (TYO:219A) said the first patient with dilated cardiomyopathy has been dosed in a domestic trial of its catheter-administered cell therapy HS-005.The Independent Safety Monitoring Committee approved the trial's continuation for the dilated cardiomyopathy cohort following a review of four-week post-administration data from this case, according to a Tokyo bourse filing on Friday.The company-sponsored study aims to expand the therapy's application beyond severe heart failure from ischaemic heart disease to include dilated cardiomyopathy, enrolling 14 patients across both disease cohorts.

TYO:219A

Asia33d ago

Heartseed Reports Positive Phase I/II Results for iPS-Derived Heart Failure Treatment HS-001

Heartseed (TYO:219A) said the Phase I/II LAPiS Study of HS-001, an allogeneic iPS cell-derived cardiomyocyte spheroid therapy for severe ischemic heart failure, met its primary safety endpoint with no concerns affecting its future approval application, according to a Tokyo bourse filing on Monday.The secondary efficacy endpoint analysis, which included independent third-party evaluations, showed supportive results across multiple measures such as cardiac pump function and reduction in heart enlargement.The company plans to submit a manufacturing and marketing approval application in Japan in the current year.

TYO:219A

Track with the FINWIRES app suite

FolioX

Track TYO:219A in your portfolio

WheelAI

Analyze TYO:219A options with the wheel strategy

StockInsider

See market sentiment on TYO:219A